BR112022012522A2 - Proteínas de ligação de tgf-beta-rii - Google Patents
Proteínas de ligação de tgf-beta-riiInfo
- Publication number
- BR112022012522A2 BR112022012522A2 BR112022012522A BR112022012522A BR112022012522A2 BR 112022012522 A2 BR112022012522 A2 BR 112022012522A2 BR 112022012522 A BR112022012522 A BR 112022012522A BR 112022012522 A BR112022012522 A BR 112022012522A BR 112022012522 A2 BR112022012522 A2 BR 112022012522A2
- Authority
- BR
- Brazil
- Prior art keywords
- antibody
- tgf
- beta
- binding proteins
- antibody fragment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—RNA viruses
- C07K16/11—Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL2024576 | 2019-12-24 | ||
| PCT/NL2020/050813 WO2021133167A1 (en) | 2019-12-24 | 2020-12-22 | Tgf-beta-rii binding proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022012522A2 true BR112022012522A2 (pt) | 2022-09-06 |
Family
ID=69700252
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022012522A BR112022012522A2 (pt) | 2019-12-24 | 2020-12-22 | Proteínas de ligação de tgf-beta-rii |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12570747B2 (https=) |
| EP (2) | EP4269433A3 (https=) |
| JP (3) | JP7633259B2 (https=) |
| KR (2) | KR20230145542A (https=) |
| CN (3) | CN116199780A (https=) |
| AR (2) | AR120914A1 (https=) |
| AU (2) | AU2020412201B2 (https=) |
| BR (1) | BR112022012522A2 (https=) |
| IL (2) | IL294181A (https=) |
| MX (2) | MX2022007919A (https=) |
| PH (1) | PH12022551527A1 (https=) |
| TW (2) | TW202417513A (https=) |
| WO (1) | WO2021133167A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116199780A (zh) * | 2019-12-24 | 2023-06-02 | 美勒斯公司 | TGF-β-RII结合蛋白质 |
| CA3231649A1 (en) * | 2021-11-19 | 2023-05-25 | Cecilia Anna Wilhelmina Geuijen | Multispecific binding moieties comprising pd-1 and tgf-brii binding domains |
| CN121736114A (zh) | 2022-12-20 | 2026-03-27 | 美勒斯公司 | FAP结合域以及结合FAP和TGF-βRII的双特异性结合部分 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001206899A (ja) * | 1999-11-18 | 2001-07-31 | Japan Tobacco Inc | ＴＧＦ−βＩＩ型受容体に対するヒトモノクローナル抗体及びその医薬用途 |
| NZ537277A (en) | 2002-07-18 | 2008-04-30 | Crucell Holland Bv | Recombinant production of mixtures of antibodies |
| PL3456190T3 (pl) | 2008-06-27 | 2022-06-06 | Merus N.V. | Wytwarzające przeciwciała transgeniczne zwierzę z gatunku myszy |
| JO3096B1 (ar) | 2008-11-07 | 2017-03-15 | Imclone Llc | الأجسام المضادة لمستقبل ii مضاد tgfb |
| JP6062375B2 (ja) * | 2011-01-06 | 2017-01-18 | グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ | Ｔｇｆ−ベータ受容体ｉｉに結合するリガンド |
| EP3470431A1 (en) | 2012-09-27 | 2019-04-17 | Merus N.V. | Bispecific igg antibodies as t cell engagers |
| JP2018527903A (ja) * | 2015-07-22 | 2018-09-27 | スカラー ロック インコーポレイテッドＳｃｈｏｌａｒ Ｒｏｃｋ，Ｉｎｃ． | Ｇｄｆ１１結合タンパク質およびその使用 |
| TW201825519A (zh) | 2016-10-18 | 2018-07-16 | 美商美國禮來大藥廠 | TGFβ受體II抗體 |
| MX2020010267A (es) | 2018-03-30 | 2020-11-06 | Merus Nv | Anticuerpo multivalente. |
| CN116199780A (zh) * | 2019-12-24 | 2023-06-02 | 美勒斯公司 | TGF-β-RII结合蛋白质 |
-
2020
- 2020-12-22 CN CN202211726462.2A patent/CN116199780A/zh active Pending
- 2020-12-22 EP EP23189839.6A patent/EP4269433A3/en active Pending
- 2020-12-22 IL IL294181A patent/IL294181A/en unknown
- 2020-12-22 JP JP2022539245A patent/JP7633259B2/ja active Active
- 2020-12-22 US US17/757,953 patent/US12570747B2/en active Active
- 2020-12-22 WO PCT/NL2020/050813 patent/WO2021133167A1/en not_active Ceased
- 2020-12-22 AU AU2020412201A patent/AU2020412201B2/en active Active
- 2020-12-22 MX MX2022007919A patent/MX2022007919A/es unknown
- 2020-12-22 PH PH1/2022/551527A patent/PH12022551527A1/en unknown
- 2020-12-22 EP EP20829233.4A patent/EP4081306A1/en active Pending
- 2020-12-22 CN CN202080094188.4A patent/CN115038497A/zh active Pending
- 2020-12-22 BR BR112022012522A patent/BR112022012522A2/pt unknown
- 2020-12-22 CN CN202211726434.0A patent/CN116375869A/zh active Pending
- 2020-12-22 KR KR1020237034290A patent/KR20230145542A/ko active Pending
- 2020-12-22 KR KR1020227023748A patent/KR20220117267A/ko active Pending
- 2020-12-23 TW TW112150430A patent/TW202417513A/zh unknown
- 2020-12-23 AR ARP200103661A patent/AR120914A1/es unknown
- 2020-12-23 TW TW109145819A patent/TW202128747A/zh unknown
-
2022
- 2022-06-23 MX MX2024002182A patent/MX2024002182A/es unknown
-
2023
- 2023-02-13 AU AU2023200779A patent/AU2023200779B2/en active Active
- 2023-04-04 JP JP2023060823A patent/JP2023076596A/ja active Pending
- 2023-07-09 IL IL304317A patent/IL304317A/en unknown
- 2023-11-07 AR ARP230102989A patent/AR130991A2/es unknown
-
2025
- 2025-02-06 JP JP2025018365A patent/JP2025083342A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL294181A (en) | 2022-08-01 |
| TW202128747A (zh) | 2021-08-01 |
| JP2023508202A (ja) | 2023-03-01 |
| EP4081306A1 (en) | 2022-11-02 |
| CN115038497A (zh) | 2022-09-09 |
| WO2021133167A1 (en) | 2021-07-01 |
| CA3165605A1 (en) | 2021-07-01 |
| JP7633259B2 (ja) | 2025-02-19 |
| MX2022007919A (es) | 2022-07-27 |
| US12570747B2 (en) | 2026-03-10 |
| EP4269433A2 (en) | 2023-11-01 |
| JP2023076596A (ja) | 2023-06-01 |
| KR20220117267A (ko) | 2022-08-23 |
| US20250270331A1 (en) | 2025-08-28 |
| CN116375869A (zh) | 2023-07-04 |
| AU2023200779B2 (en) | 2026-02-19 |
| EP4269433A3 (en) | 2024-05-22 |
| MX2024002182A (es) | 2024-05-03 |
| TW202417513A (zh) | 2024-05-01 |
| CN116199780A (zh) | 2023-06-02 |
| IL304317A (en) | 2023-09-01 |
| AR130991A2 (es) | 2025-02-05 |
| AU2020412201B2 (en) | 2026-02-12 |
| KR20230145542A (ko) | 2023-10-17 |
| JP2025083342A (ja) | 2025-05-30 |
| AR120914A1 (es) | 2022-03-30 |
| PH12022551527A1 (en) | 2024-01-29 |
| AU2020412201A1 (en) | 2022-07-14 |
| AU2023200779A1 (en) | 2023-03-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021011431A2 (pt) | Anticorpo monoclonal ou um fragmento de anticorpo do mesmo que se liga ao ccr8, seu uso, bem como composição farmacêutica, polinucleotídeo, vetor de expressão e kit | |
| EA202090104A1 (ru) | Молекулы антител к cd73 и пути их применения | |
| BR112019010943A8 (pt) | Usos de um anticorpo que se liga especificamente ao domínio extracelular de tigit humano para a inibição do crescimento do tumor, composição que compreende o dito anticorpo, polinucleotídeo, vetor e célula | |
| BR112022009938A2 (pt) | Compostos macrocíclicos substituídos e métodos de tratamento relacionados | |
| BR112019023754A2 (pt) | anticorpo anti-sirpalpha ou um fragmento de ligação ao antígeno do mesmo, composição farmacêutica, e, combinação do anticorpo anti-sirpalpha ou da composição farmacêutica. | |
| CL2012002433A1 (es) | Anticuerpo aislado o fragmento inmunoreactivo del mismo que comprende un dominio variable que se une específicamente a un dominio extracelular del receptor b7-h3; ácido nucleico que lo codifica; hibridoma que lo secreta; reactivo de redireccionamiento de doble afinidad (dart) que lo comprende; composición farmacéutica que lo comprende; y su uso para tratar cáncer. | |
| BR112017005517A2 (pt) | anticorpos antiage para o tratamento de inflama-ção e de transtornos autoimunes | |
| BR112018070998A2 (pt) | proteínas de ligação triespecíficas e/ou trivalentes | |
| BR112019010265A2 (pt) | anticorpos anti_cd137 inovadores e usos dos mesmos | |
| BR112018068340A2 (pt) | imunoglobulinas de ligação ao tgfss1 e usos destas | |
| BR112022012522A2 (pt) | Proteínas de ligação de tgf-beta-rii | |
| CO2018000410A2 (es) | Moléculas de anticuerpo que se unen a cd79 | |
| CO2018000104A2 (es) | Moléculas de anticuerpo que se unen a cd22 | |
| BR112017013599A2 (pt) | composição farmacêutica, e, método para prevenir, tratar ou melhorar um ou mais sintomas de um tumor maligno associado à mutação de kras. | |
| BR112014018481A2 (pt) | anticorpo monoclonal ou policlonal ou um fragmento de ligação a antígeno do mesmo, polinucleotídeo, anticorpo monoclonal, vetor, hibridoma, anticorpo, hibridoma 5166-2 e/ou 5166-9, anticorpo ou fragmento de ligação a antígeno, composição farmacêutica, uso do anticorpo ou fragmento de ligação a anticorpo, método para tratar câncer, método para diagnosticar câncer em um indivíduo, anticorpo, método, composição ou uso | |
| BR112017025080A2 (pt) | composto conjugado de fármaco com anticorpo anti-cd123, composição conjugada de fármaco com anticorpo, método de tratamento de um paciente que tem um câncer que expressa cd123, composição farmacêutica, e, anticorpo intacto ou fragmento de ligação de antígeno | |
| BR112018074978A2 (pt) | anticorpos para alfa-sinucleína e usos dos mesmos | |
| BR112017003194B8 (pt) | Anticorpo ou fragmento de ligação ao antígeno do mesmo que se liga especificamente a lag3 humano, composição, e, uso do anticorpo ou de um fragmento de ligação ao antígeno do mesmo e da composição | |
| BR112022004408A2 (pt) | Anticorpo monoclonal humano alvejando ykl-40 | |
| BR112017002703A2 (pt) | anticorpos específicos de mmp9. | |
| BR112018003794A2 (pt) | composições e métodos para o tratamento da dor | |
| CL2025000063A1 (es) | Anticuerpos anti-abeta | |
| BR112020006248A8 (pt) | Anticorpo anti-bcma com alta afinidade para bcma, polinucleotídeo, vetor de expressão, célula hospedeira, método para produção do dito anticorpo, composição farmacêutica compreendendo o mesmo e uso do anticorpo para prevenção ou tratamento de câncer | |
| EA201791691A1 (ru) | ОДНОДОМЕННЫЕ АНТИТЕЛА, НАПРАВЛЕННЫЕ НА CD1d | |
| BR112019023820A2 (pt) | moduladores duplos de receptor de farnesoide x e epóxido hidrolas solúvel |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B154 | Notification of filing of divisional application [chapter 15.50 patent gazette] |
Free format text: O PEDIDO FOI DIVIDIDO NO BR122023027661-2 PROTOCOLO 870230114727 EM 28/12/2023 11:23. |
|
| B25G | Requested change of headquarter approved |
Owner name: MERUS N.V. (NL) |